Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Perseus Proteomics, Inc. ( (JP:4882) ) has shared an announcement.
Perseus Proteomics Inc. announced its business forecasts for the fiscal year ending March 31, 2025, with a focus on licensing agreements for its pipeline projects PPMX-T002 and PPMX-T003. The company anticipates significant R&D and administrative expenses, impacting its financial results. Despite challenges in forecasting due to incomplete licensing activities, Perseus Proteomics remains committed to maximizing the value of its projects, which could influence its market positioning and stakeholder interests.
More about Perseus Proteomics, Inc.
Perseus Proteomics Inc. operates in the biotechnology industry, focusing on the development and licensing of proteomics-based therapeutic products. The company is engaged in pipeline projects aimed at maximizing the value of its proprietary technologies.
YTD Price Performance: 42.17%
Average Trading Volume: 970,200
Technical Sentiment Signal: Sell
Current Market Cap: Yen11.78B
Learn more about 4882 stock on TipRanks’ Stock Analysis page.